OBJECTIVE: To compare gene expression profiles between ankylosing spondylitis (AS) and undifferentiated spondylarthritis (uSpA) patients with inflammatory low back pain. METHODS: Peripheral blood mononuclear cells (PBMCs) from patients with AS, patients with uSpA, and healthy subjects were screened using genome-wide microarrays, followed by validation by real-time polymerase chain reaction (PCR). RESULTS: Microarray profiling and real-time PCR assays showed only minor differences between AS patients and healthy subjects. In contrast, 20 genes were strikingly more highly expressed in uSpA patients. Regulator of G protein signaling 1 (RGS1) was identified as the most useful biomarker for distinguishing uSpA patients, and to a lesser extent AS patients, from control subjects (P = 2.3 x 10(-7) and 6.7 x 10(-3), respectively). These findings were verified in an independent cohort that also included patients with rheumatoid arthritis and patients with mechanical low back pain. The receiver operating characteristic area under the curve values in the first and second cohorts of uSpA patients were 0.99 and 0.93, respectively (P = 1 x 10(-4)). To evaluate the possible derivation of RGS1, we cultured a monocyte-derived cell line with a panel of cytokines and chemokines. RGS1 was significantly induced either by tumor necrosis factor alpha (TNFalpha) or by interleukin-17 (IL-17). CONCLUSION: Our findings indicate that uSpA PBMCs carry strikingly more highly expressed genes compared with PBMCs from AS patients or healthy subjects, and that TNFalpha- and IL-17-inducible RGS1 is a potential biomarker for uSpA, and to a lesser extent for AS, with inflammatory low back pain.
OBJECTIVE: To compare gene expression profiles between ankylosing spondylitis (AS) and undifferentiated spondylarthritis (uSpA) patients with inflammatory low back pain. METHODS: Peripheral blood mononuclear cells (PBMCs) from patients with AS, patients with uSpA, and healthy subjects were screened using genome-wide microarrays, followed by validation by real-time polymerase chain reaction (PCR). RESULTS: Microarray profiling and real-time PCR assays showed only minor differences between AS patients and healthy subjects. In contrast, 20 genes were strikingly more highly expressed in uSpApatients. Regulator of G protein signaling 1 (RGS1) was identified as the most useful biomarker for distinguishing uSpApatients, and to a lesser extent AS patients, from control subjects (P = 2.3 x 10(-7) and 6.7 x 10(-3), respectively). These findings were verified in an independent cohort that also included patients with rheumatoid arthritis and patients with mechanical low back pain. The receiver operating characteristic area under the curve values in the first and second cohorts of uSpApatients were 0.99 and 0.93, respectively (P = 1 x 10(-4)). To evaluate the possible derivation of RGS1, we cultured a monocyte-derived cell line with a panel of cytokines and chemokines. RGS1 was significantly induced either by tumor necrosis factor alpha (TNFalpha) or by interleukin-17 (IL-17). CONCLUSION: Our findings indicate that uSpA PBMCs carry strikingly more highly expressed genes compared with PBMCs from AS patients or healthy subjects, and that TNFalpha- and IL-17-inducible RGS1 is a potential biomarker for uSpA, and to a lesser extent for AS, with inflammatory low back pain.
Authors: M Rudwaleit; D van der Heijde; R Landewé; J Listing; N Akkoc; J Brandt; J Braun; C T Chou; E Collantes-Estevez; M Dougados; F Huang; J Gu; M A Khan; Y Kirazli; W P Maksymowych; H Mielants; I J Sørensen; S Ozgocmen; E Roussou; R Valle-Oñate; U Weber; J Wei; J Sieper Journal: Ann Rheum Dis Date: 2009-03-17 Impact factor: 19.103
Authors: M Dougados; S van der Linden; R Juhlin; B Huitfeldt; B Amor; A Calin; A Cats; B Dijkmans; I Olivieri; G Pasero Journal: Arthritis Rheum Date: 1991-10
Authors: Javier Rangel; Mehdi Nosrati; Stanley P L Leong; Chris Haqq; James R Miller; Richard W Sagebiel; Mohammed Kashani-Sabet Journal: Am J Surg Pathol Date: 2008-08 Impact factor: 6.394
Authors: X B Wang; J J Ellis; D J Pennisi; X Song; J Batra; K Hollis; L A Bradbury; Z Li; T J Kenna; M A Brown Journal: Genes Immun Date: 2017-08-24 Impact factor: 2.676
Authors: Deena L Gibbons; Lucie Abeler-Dörner; Tim Raine; Il-Young Hwang; Anett Jandke; Melanie Wencker; Livija Deban; Christopher E Rudd; Peter M Irving; John H Kehrl; Adrian C Hayday Journal: J Immunol Date: 2011-07-27 Impact factor: 5.422
Authors: Fernando M Pimentel-Santos; Dário Ligeiro; Mafalda Matos; Ana F Mourão; José Costa; Helena Santos; Anabela Barcelos; Fátima Godinho; Patricia Pinto; Margarida Cruz; João E Fonseca; Henrique Guedes-Pinto; Jaime C Branco; Matthew A Brown; Gethin P Thomas Journal: Arthritis Res Ther Date: 2011-04-07 Impact factor: 5.156
Authors: Suthesh Sivapalaratnam; Hanneke Basart; Nicholas A Watkins; Stepanie Maiwald; Augusto Rendon; Unni Krishnan; Brigitte M Sondermeijer; Esther E Creemers; Sara J Pinto-Sietsma; Kees Hovingh; Willem H Ouwehand; John J P Kastelein; Alison H Goodall; Mieke D Trip Journal: PLoS One Date: 2012-02-21 Impact factor: 3.240
Authors: Gethin P Thomas; Ran Duan; Allison R Pettit; Helen Weedon; Simranpreet Kaur; Malcolm Smith; Matthew A Brown Journal: BMC Musculoskelet Disord Date: 2013-12-15 Impact factor: 2.362
Authors: Lovro Lamot; Fran Borovecki; Lana Tambic Bukovac; Mandica Vidovic; Marija Perica; Kristina Gotovac; Miroslav Harjacek Journal: PLoS One Date: 2014-12-15 Impact factor: 3.240